$155.30 -$1.40 (-0.9%)

04:15 PM EST on 01/24/20

Charles River Laboratories (NYSE:CRL)

CAPS Rating: 4 out of 5

The Company is a global provider of solutions that advance the drug discovery and development process. It provides the animal research models required in research and development for new drugs, devices and therapies.

Current Price $155.30 Mkt Cap $7.6B
Open $157.17 P/E Ratio 32.48
Prev. Close $155.30 Div. (Yield) $0.00 (0.0%)
Daily Range $154.77 - $157.27 Volume 89,472
52-Wk Range $150.73 - $161.22 Avg. Daily Vol. 305,760

Caps

How do you think NYSE:CRL will perform against the market?

Add Stock to CAPS Watchlist

All Players

212 Outperform
12 Underperform
 

All-Star Players

39 Outperform
4 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Recent Community Commentary

Read the most recent pitches from players about CRL.

Recs

0
Member Avatar MaestroFool (87.66) Submitted: 12/15/2019 4:28:09 PM : Outperform Start Price: $123.48 NYSE:CRL Score: +12.32

Charles River breeds and sells lab rats, mice, bunnies, guinea pigs of all shapes and sizes and in various states of sickness, health, obesity, and even already having had various clinical procedures and operations. This company's work is unpleasant, but essential for the clinical trials and research behind the groundbreaking treatments and therapies that allow us to live longer and healthier.

Recs

0
Member Avatar kenjotto (< 20) Submitted: 8/10/2011 10:16:21 AM : Outperform Start Price: $30.59 NYSE:CRL Score: +216.51

Activist inspired turn around is progressing well. They're repurchasing shares, cutting underperforming segments, and increasing and improving their sales to key end users. As big pharma looks to revive its pipeline, they'll come to CRL. Plus, CRL is only #2 in the CRO industry, so they have runway ahead of them!

Recs

0
Member Avatar fdude71 (< 20) Submitted: 12/29/2010 7:36:40 AM : Outperform Start Price: $35.57 NYSE:CRL Score: +175.59

Bought RL at $35.57.

CRL is the dominant provider of lab rats (moat) and provides "research outsourcing" to the "Big Pharmas" (double the moat if you consider the tight relationship needed to get contracts in this field).

This is a cyclical business... at -or near- the bottom of the weakness cycle.
Recent stock buybacks.
A group of activist investors owns 15% of CRL.

I expect this to be a very profitable play, though there will be bumps along the ride - snag this around $30/piece if you can- given the fairly high valuation of the business.

Leaderboard

Find the members with the highest scoring picks in CRL.

Score Leader

tskephart

tskephart (94.35) Score: +323.81

The Score Leader is the player with the highest score across all their picks in CRL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
tskephart 94.35 11/26/2008 Outperform 3Y $21.87 +610.11% +286.29% +323.81 1 Comment
dingo72 84.23 12/3/2008 Outperform 3Y $21.94 +607.84% +292.37% +315.47 0 Comment
5st4 66.63 1/9/2009 Outperform NS $23.91 +549.52% +267.09% +282.43 0 Comment
DFT2007 99.83 11/17/2008 Outperform NS $23.35 +565.10% +290.54% +274.56 0 Comment
jackjjr 83.23 11/17/2011 Outperform 5Y $28.96 +436.26% +166.83% +269.42 0 Comment
dog1350 68.16 12/11/2008 Outperform 5Y $24.17 +542.53% +276.74% +265.79 0 Comment
kagold 84.51 10/4/2011 Outperform 5Y $27.68 +461.05% +203.48% +257.58 0 Comment
elzbal 31.90 10/17/2011 Outperform 1Y $29.43 +427.69% +171.57% +256.12 0 Comment
JohnGabriel 86.66 9/29/2011 Outperform 5Y $28.97 +436.07% +183.73% +252.34 0 Comment
CMFGouldberg 77.82 10/3/2011 Outperform 5Y $28.18 +451.10% +199.12% +251.98 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CRL.